Medpace Holdings Inc vs Monster Beverage Corp — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Monster Beverage Corp trades at $95.32 (market cap $93.35B). The key difference: Monster Beverage Corp is far larger — about 6.2× Medpace Holdings Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | MNST | |
|---|---|---|
Market Cap | $15.08B | $93.35B |
Sector | Technology | Consumer Staples |
52-Week High | $620.59 | $99.94 |
52-Week Low | $308.88 | $58.75 |
Enterprise Value | $14.55B | $91.65B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Monster Beverage (MNST) trades at $95.79, down 1.75% over 24 hours but near its 52-week high of $99.53. The stock shows strong fundamentals with consistent earnings beats, revenue growth to $8.29B in 2025, and robust profitability margins. A 2-for-1 stock split announced for August 2026 reflects confidence, while technical indicators signal a bullish trend with support at $94.
Outlook remains positive driven by international expansion and product innovation, with a consensus price target of $97.83 offering modest upside. Risks include high valuation multiples and competitive pressures in the energy drink sector. Analyst sentiment is predominantly bullish, supporting a favorable investment case for growth-oriented investors.
Trailing returns across standard periods
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →